acut
chronic
infect
especi
induc
gramneg
bacteria
associ
increas
risk
thrombosi
atherosclerot
diseas
littl
known
underli
cellular
mechan
respons
risk
lipopolysaccharid
lp
compon
cell
wall
gramneg
bacteria
antigen
initi
inflamm
innat
immun
respons
interact
tolllik
receptor
express
surfac
cell
includ
leukocyt
platelet
physiolog
condit
platelet
leukocyt
circul
quiescent
state
interact
howev
activ
pathophysiolog
condit
associ
infect
platelet
chang
shape
secret
prothrombogen
inflammatori
cellular
adhes
molecul
alpha
densegranul
caus
platelet
adher
leukocyt
andor
vascular
endothelium
physiolog
consequ
stimuli
associ
infect
like
lp
stimul
acut
sustain
exampl
halflif
platelet
shorten
activ
state
newli
form
platelet
bone
marrow
megakaryocyt
increas
within
seven
day
follow
singl
acut
intraven
inject
lp
mice
howev
cellular
event
specif
occur
among
blood
element
contribut
shorten
halflif
increas
activ
state
platelet
remain
clarifi
one
mechan
offer
explain
infect
contribut
onset
progress
cardiovascular
diseas
increas
product
proinflammatori
cytokin
howev
explan
address
product
inflammatori
cytokin
might
proceed
ident
cell
type
target
lp
stimul
platelet
may
repres
one
first
blood
born
element
react
lp
stimul
chang
platelet
reactiv
via
seem
occur
prior
sustain
chang
circul
level
cytokin
altern
compar
activ
leukocyt
well
platelet
result
format
cellderiv
microvesicl
mv
may
contribut
increas
thrombogen
propens
blood
proinflammatori
immun
process
thu
cardiovascular
risk
clarifi
interact
blood
element
platelet
leukocyt
set
activ
might
provid
insight
infect
initi
facilit
progress
cardiovascular
diseas
mv
cell
membranederiv
vesicl
rang
size
micron
diamet
shed
respons
cellular
activ
cellcel
interact
apoptosi
cellderiv
vesicl
interfac
activ
cellular
compon
blood
vascular
wall
solubl
compon
blood
associ
immun
includ
respons
infect
exampl
phosphatidylserin
ps
surfac
mv
provid
catalyt
site
prothrombinas
complex
gener
thrombin
need
convers
fibrinogen
fibrin
format
clot
furthermor
exposur
dilut
blood
lp
vitro
increas
product
plateletderiv
well
tissu
factor
posit
mv
within
hour
experi
provid
evid
lp
modul
platelet
activ
provid
insight
interact
platelet
blood
element
within
earliest
stage
activ
especi
time
point
prior
period
measur
chang
circul
cytokin
observ
vivo
therefor
present
studi
design
test
hypothesi
acut
exposur
sentinel
dose
lp
would
induc
mv
product
exchang
specif
proteinsreceptor
platelet
leukocyt
via
activ
mv
transport
biolog
activ
cell
content
includ
cell
surfac
receptor
among
cell
identifi
use
antibodi
specif
cell
antigen
ie
platelet
leukocytespecif
antigen
respect
mv
deriv
platelet
andor
leukocyt
distinguish
cell
specif
fluorescein
conjug
antigen
stain
use
calibr
flow
cytometri
four
eight
month
old
male
femal
mice
wild
type
wt
mice
homozyg
delet
obtain
jackson
laboratori
bar
harbor
main
mice
express
mutat
origin
describ
strain
mice
sex
age
use
randomli
variou
protocol
mice
hous
temperaturecontrol
environ
rel
humid
lightdark
cycl
fed
standard
chow
experi
approv
institut
anim
care
use
committe
mayo
clinic
rochest
mn
ultrapur
ecoli
lipopolysaccharid
lp
ligand
product
number
tlrlpelp
pepinhmyd
product
number
tlrlpimyd
pepinhtrif
product
number
tlrlpitrif
inhibitori
peptid
invivogen
san
diego
ca
prepar
suggest
supplier
mous
thrombin
bovin
serum
albumin
purchas
sigma
chemic
co
st
loui
mo
usa
cellular
origin
antigen
determin
use
platelet
rat
antimous
antibodi
total
leukocyt
rat
antimous
antibodi
membran
specif
fluorescein
conjug
phycoerythrin
pe
fluorescein
isothiocyan
fitc
antibodi
flow
cytometri
pe
fitcconjug
annexinv
match
isotyp
control
antibodi
purchas
bd
pharmingen
intern
san
diego
ca
reagent
solvent
use
studi
analyticalreag
grade
blood
collect
retroorbit
sinu
plexu
wild
type
mice
silicon
capillari
tube
coat
hirudin
thrombin
inhibitor
soybean
trypsin
inhibitor
sti
factor
xa
inhibitor
ml
polypropylen
tube
contain
hirudin
mm
sti
vitro
experi
anticoagul
blood
aliquot
pair
tube
within
min
collect
measur
vehicletr
control
tube
lpstreat
tube
could
analyz
mous
time
point
vehicl
salin
lp
ngml
ad
one
pair
aliquot
blood
design
time
point
minut
addit
vehicl
lp
whole
blood
aliquot
dilut
hepeshank
buffer
mm
nacl
mm
kcl
mm
mm
mm
mm
hepe
ph
mgml
albumin
sti
stain
platelet
posit
leukocyt
antigen
leukocyt
posit
platelet
antigen
remain
blood
use
prepar
platelet
free
plasma
pfp
mv
analysi
vivo
experi
male
mice
month
age
receiv
singl
inject
lp
ngmous
nggm
bodi
weight
tail
vein
seven
day
inject
blood
collect
describ
analysi
platelet
antigen
posit
leukocyt
subpopul
flow
cytometri
trigger
total
leukocyt
marker
allophycocyanin
posit
event
contain
granulocyt
monocyt
lymphocyt
apoptot
bodi
separ
light
forward
side
scatter
blot
analysi
gate
subtyp
leukocyt
base
size
gate
verifi
use
cell
specif
antibodi
granulocyt
monocyt
tlymphocyt
blymphocyt
differenti
leukocyt
popul
subject
twocolor
analysi
differenti
leukocyt
posit
phosphatidylserin
platelet
antigen
annexinvfitc
vs
leukocyt
neg
phosphatidylserin
platelet
antigen
percentag
posit
event
calcul
set
threshold
isotyp
control
antibodi
blood
sampl
mous
divid
two
aliquot
one
dilut
salin
control
salin
contain
lp
ngml
final
concentr
sampl
incub
timepoint
prior
lp
vehicl
min
aliquot
remov
sampl
dilut
paraformaldehyd
incub
addit
min
sampl
dilut
pb
pore
membranefilt
centrifug
min
supern
contain
platelet
remov
place
new
vial
use
imag
analysi
aliquot
platelet
suspens
dilut
pb
drop
place
glass
slide
coverslip
seal
glue
platelet
imag
darkfield
mode
use
light
microscop
olympu
oilimmers
len
coupl
cytoviva
illumin
system
cytoviva
inc
auburn
al
scan
corner
coverslip
platelet
field
count
total
platelet
categor
accord
shape
morpholog
discoid
irregular
flatten
pseudopodia
whether
exhibit
membran
granul
aggreg
aggreg
count
number
platelet
categori
express
percentag
total
platelet
count
dilut
whole
blood
incub
peconjug
platelet
leukocytespecif
antibodi
respect
separ
annexin
vfitc
bind
phosphatidylserin
min
paraformaldehyd
ad
match
fluorescein
conjug
isotyp
control
antibodi
use
simultan
stain
set
threshold
exclud
nonspecif
bind
interact
cell
platelet
leukocyt
cellderiv
mv
ps
express
platelet
leukocyt
analyz
flow
cytometri
bd
bioscienc
san
jose
ca
platelet
identifi
forward
side
scatter
fluorescein
conjug
antibodi
event
gate
sampl
respect
figur
buffer
antibodi
filter
twice
membran
millipor
filter
mv
analysi
platelet
free
plasma
pfp
prepar
doubl
centrifug
min
pfp
dilut
hepeshank
buffer
incub
fitcconjug
annexinv
peconjug
antibodi
min
dark
time
hank
balanc
salt
buffer
ph
mm
ad
match
isotyp
control
antibodi
use
set
threshold
exclud
nonspecif
bind
mv
quantifi
base
count
calibr
bead
bead
ad
immedi
sampl
prior
analysi
flow
cytometri
bd
bioscienc
san
jose
ca
previous
describ
studi
mv
defin
event
diamet
use
size
calibr
bead
posit
annexinv
platelet
leukocyt
specif
marker
lp
stimul
signal
analyz
introduc
trif
inhibitori
peptid
describ
studi
anticoagul
blood
wt
mice
aliquot
six
tube
treat
pepinhcontrol
vehicl
pepinhmyd
inhibitori
peptid
bind
block
stimul
signal
andor
pepinhtrif
bind
trif
block
stimul
trif
signal
alon
combin
min
either
salin
lp
ngml
ad
one
hour
time
aliquot
dilut
analysi
flow
cytometri
measur
cellular
origin
mv
platelet
posit
leukocyt
antigen
leukocyt
posit
platelet
antigen
data
present
percentag
fold
increas
pair
vehicl
lp
treat
blood
sampl
time
point
data
present
mean
sem
n
number
anim
use
experi
statist
signific
evalu
pair
unpair
twotail
student
ttest
statist
signific
accept
p
prior
addit
lp
platelet
wt
mice
discoid
form
aggreg
extend
psuedopodia
figur
surfac
express
ps
platelet
leukocyt
similar
wt
mice
within
group
mice
express
ps
significantli
lower
leukocyt
platelet
tabl
first
hour
incub
blood
lp
platelet
wt
mice
underw
shape
chang
extend
pseudopodia
form
aggreg
figur
within
first
hour
neither
surfac
express
ps
either
platelet
leukocyt
number
platelet
leukocytederiv
mv
chang
significantli
wt
mice
mice
tabl
howev
number
platelet
posit
leukocytespecif
antigen
defin
plateletg
flow
cytomet
figur
increas
significantli
timedepend
manner
blood
wt
mice
mice
figur
use
total
leukocyt
specif
antibodi
defin
total
leukocyt
number
leukocyt
posit
plateletspecif
antigen
increas
significantli
either
wt
mice
figur
blood
wt
mice
percentag
platelet
posit
leukocyt
antigen
reduc
significantli
extent
trif
figur
combin
trif
reduc
percentag
aggreg
greater
extent
either
alon
seven
day
follow
singl
intraven
inject
sentinel
dose
lp
nggm
bodi
weight
ngmous
none
platelet
posit
leukocyt
antigen
contrari
compar
leukocyt
obtain
anim
treat
vehicl
week
lp
inject
mous
granulocyt
monocyt
significantli
posit
platelet
antigen
seven
day
singl
lp
inject
figur
apoptot
bodi
also
stain
posit
platelet
antigen
figur
within
one
hour
exposur
whole
blood
concentr
lp
threshold
effect
cytokin
product
vivo
platelet
becom
posit
leukocyt
antigen
plateletleukocyt
interact
requir
signal
dual
antigen
posit
platelet
observ
blood
deriv
wild
type
mice
furthermor
peptid
inhibitor
signal
molecul
block
interact
event
occur
within
hour
initi
exposur
lp
addit
effect
lp
stimul
sustain
least
day
past
initi
lp
exposur
leukocyt
express
platelet
antigen
time
point
collect
result
identifi
acut
rapid
signal
mechan
sentinelgrad
acut
infect
alter
blood
hemostasi
sustain
leukocyt
activ
may
contribut
progress
cardiovascular
diseas
